The Figure shows the baseline characteristics of the patients in RE-LY, which are typical of a population with AFib with associated structural disorders.[96]
The mean age was 71 years, although a significant percentage, 40%, were aged ≥75 years.  As usual there were more men than women.  The mean CHADS₂ score was 2.2, but of note (highlighted in light blue), about one third of the patients had a CHADS₂ score ≥3, which becomes relevant when comparing these results to the ROCKET AF trial with rivaroxaban (discussed below). 

 Reiffel JA. Am J Med 2013; 126: 00-00.